LobbyingVerax Biomedical lobbying by quarter
Verax Biomedical's latest lobbying report covers Q2 2023, at $14K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Verax Biomedical
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $90K | 2 |
| Q1 2023 | $90K | 2 |
| Q2 2023 | $14K | 2 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$164K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| S-3 Group | $134K | 3 quarters |
| Fierce Government Relations | $60K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/07/20for Q2 2023 | S-3 Group | $14K |
| 23/07/20for Q2 2023 | Fierce Government Relations | Under $5,000 |
| 23/04/20for Q1 2023 | Fierce Government Relations | $30K |
| 23/04/20for Q1 2023 | S-3 Group | $60K |
| 23/01/20for Q4 2022 | S-3 Group | $60K |
| 23/01/20for Q4 2022 | Fierce Government Relations | $30K |